$14.22
5.18% yesterday
Nasdaq, Nov 21, 10:03 pm CET
ISIN
US61225M1027
Symbol
GLUE

Monte Rosa Therapeutics Inc Stock price

$14.22
+4.63 48.28% 1M
+10.21 254.61% 6M
+7.28 104.90% YTD
+5.87 70.30% 1Y
+6.07 74.48% 3Y
-6.96 32.86% 5Y
-6.96 32.86% 10Y
-6.96 32.86% 20Y
Nasdaq, Closing price Fri, Nov 21 2025
+0.70 5.18%
ISIN
US61225M1027
Symbol
GLUE
Industry

Key metrics

Basic
Market capitalization
$926.0m
Enterprise Value
$534.7m
Net debt
positive
Cash
$391.3m
Shares outstanding
61.8m
Valuation (TTM | estimate)
P/E
56.9 | negative
P/S
5.1 | 7.3
EV/Sales
3.0 | 4.2
EV/FCF
3.7
P/B
3.8
Financial Health
Equity Ratio
50.8%
Return on Equity
-32.6%
ROCE
2.1%
ROIC
27.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$181.5m | $126.2m
EBITDA
$16.8m | $-2.1m
EBIT
$8.5m | $-17.5m
Net Income
$21.0m | $-20.1m
Free Cash Flow
$145.0m
Growth (TTM | estimate)
Revenue
1,111.9% | 66.9%
EBITDA
113.9% | 97.2%
EBIT
106.6% | 78.4%
Net Income
117.5% | 72.3%
Free Cash Flow
331.0%
Margin (TTM | estimate)
Gross
-
EBITDA
9.3% | -1.6%
EBIT
4.7%
Net
11.5% | -16.0%
Free Cash Flow
79.9%
More
EPS
$0.3
FCF per Share
$2.3
Short interest
16.0%
Employees
142
Rev per Employee
$530.0k
Show more

Is Monte Rosa Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Monte Rosa Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

Buy
87%
Hold
13%

Financial data from Monte Rosa Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
182 182
1,112% 1,112%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
2% 2%
19%
- Research and Development Expense 138 138
26% 26%
76%
17 17
114% 114%
9%
- Depreciation and Amortization 8.33 8.33
5% 5%
5%
EBIT (Operating Income) EBIT 8.51 8.51
107% 107%
5%
Net Profit 21 21
118% 118%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Monte Rosa Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Monte Rosa Therapeutics Inc Stock News

Neutral
GlobeNewsWire
14 days ago
Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis Initial data from a Phase 1 study of MRT-8102 in healthy volunteers and elevated CVD-risk subjects on track for first half of 2026 Poster presentation on November 8 at 10:30 a.m. CST ...
Neutral
GlobeNewsWire
16 days ago
Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise payments, milestones, and tiered royalties Phase 1 study of NEK7-directed MGD MRT-8102 underway, investigating a potential novel approach to treat inflammatory diseases driven by the NLRP3 i...
Neutral
GlobeNewsWire
19 days ago
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference (Boston, ...
More Monte Rosa Therapeutics Inc News

Company Profile

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Head office United States
CEO Markus Warmuth
Employees 142
Founded 2019
Website www.monterosatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today